Lab study: Navtemadlin strengthens melanoma-targeting T cells
UCLA laboratory data show navtemadlin temporarily activates p53, reducing T-cell exhaustion and improving melanoma-cell killing; dosing and animal testing remain essential.
Topic
T Cell Therapy
Topic